Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Javed

Showing results (381-390 of 392) with videos related to

Pageof 40
Sort By:
Annals of Surgery|June 9, 2017
Characterization and Optimal Management of High-risk Pancreatic Anastomoses During PancreatoduodenectomyBrett L Ecker, Matthew T McMillan, Horacio J Asbun, et al.
Annals of Surgery|January 31, 2025
Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOXIngmar F Rompen, Thomas F Stoop, Stijn van Roessel, et al.
Acta Neuropathologica|August 30, 2019
MSTO1 mutations cause mtDNA depletion, manifesting as muscular dystrophy with cerebellar involvementS Donkervoort, R Sabouny, P Yun, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|May 21, 2026
Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation of prognostic modelsAmmar A Javed, Mahsoem Ali, Omar Mahmud, et al.
Journal of the National Cancer Institute|September 3, 2025
Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinomaAmmar A Javed, Asad Saulat Fatimi, Ingmar F Rompen, et al.
Cancer Letters|October 31, 2020
Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017Ding Ding, Ammar A Javed, Dea Cunningham, et al.
Journal of the National Cancer Institute|May 16, 2019
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-AnalysisQuisette P Janssen, Stefan Buettner, Mustafa Suker, et al.
British Journal of Cancer|May 6, 2025
Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an international multicentre studyThomas F Stoop, Y H Andrew Wu, Atsushi Oba, et al.
Annals of Surgery|March 5, 2019
Benchmarks in Pancreatic Surgery: A Novel Tool for Unbiased Outcome ComparisonsPatricia Sánchez-Velázquez, Xavier Muller, Giuseppe Malleo, et al.
JAMA Network Open|June 18, 2024
Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative ChemotherapyThomas F Stoop, Atsushi Oba, Y H Andrew Wu, et al.
Pageof 40

Showing results (381-390 of 392) with videos related to

Sort By:
Pageof 40
Annals of Surgery|June 9, 2017
Characterization and Optimal Management of High-risk Pancreatic Anastomoses During PancreatoduodenectomyBrett L Ecker, Matthew T McMillan, Horacio J Asbun, et al.
Annals of Surgery|January 31, 2025
Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOXIngmar F Rompen, Thomas F Stoop, Stijn van Roessel, et al.
Acta Neuropathologica|August 30, 2019
MSTO1 mutations cause mtDNA depletion, manifesting as muscular dystrophy with cerebellar involvementS Donkervoort, R Sabouny, P Yun, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|May 21, 2026
Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation of prognostic modelsAmmar A Javed, Mahsoem Ali, Omar Mahmud, et al.
Journal of the National Cancer Institute|September 3, 2025
Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinomaAmmar A Javed, Asad Saulat Fatimi, Ingmar F Rompen, et al.
Cancer Letters|October 31, 2020
Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017Ding Ding, Ammar A Javed, Dea Cunningham, et al.
Journal of the National Cancer Institute|May 16, 2019
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-AnalysisQuisette P Janssen, Stefan Buettner, Mustafa Suker, et al.
British Journal of Cancer|May 6, 2025
Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an international multicentre studyThomas F Stoop, Y H Andrew Wu, Atsushi Oba, et al.
Annals of Surgery|March 5, 2019
Benchmarks in Pancreatic Surgery: A Novel Tool for Unbiased Outcome ComparisonsPatricia Sánchez-Velázquez, Xavier Muller, Giuseppe Malleo, et al.
JAMA Network Open|June 18, 2024
Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative ChemotherapyThomas F Stoop, Atsushi Oba, Y H Andrew Wu, et al.
Pageof 40